Bristol Myers Squibb shared the news that the company’s Phase III clinical trial investigating the safety and efficacy of Opdivo and Yervoy combination therapy (NCT03036098) in patients with metastatic urothelial carcinoma failed to meet the predetermined primary endpoint. A posthoc analysis was shared by Synairgen suggesting that, despite SNG001 failing to meet the primary endpoint of patient recovery and subsequent hospital discharge in a Phase III study for patients hospitalized with COVID-19 who required supplemental oxygen treatment, they may benefit from receiving the treatment.
BridgeBio augments comeback week with sale of priority review voucherBristol Myers Squibb, Business, FDA, Layoffs, Molybdenum cofactor deficiency (MoCD) Type A, PDUFA, Priority Review, Priority Review Status, Priority Review Voucher, Rare Diseases, Rare Pediatric Disease Priority Review Voucher, Sales, Therapeutics
One day after BridgeBio Pharma struck a nearly $1 billion oncology pact with Bristol Myers Squibb, the California-based company announced plans to sell a priority review voucher received in February.
BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.
Development of a new cancer treatment pioneered by Roche was thrown into doubt on May 11 when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s shares.
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. On May 4, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
FDA approves Bristol Myers’ oral heart disease drugApprovals, Boxed Warning, Bristol Myers Squibb, Cardiac Arrest, Cardiac myosin inhibitors, FDA, Genetic Inflammatory Conditions, Heart Disease, Heart Muscles, Hypertrophic cardiomyopathy (HCM), Left Ventricular Ejection Fraction (LVEF), Oral Therapy, Therapeutics, Wholesale Acquisition Cost
The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.
Nektar Cuts 70% of Workforce on Heels of BMS-Partnered CollapseAutoimmune Disease, Bladder Cancer, Blockbusters, Bristol Myers Squibb, Business, Cancer, CAR-T Therapy, Checkpoint Inhibitors, Clinical Trials, Collaborations, Job Cuts, Melanoma, Product Pipeline, R&D, Renal Cell Carcinoma (RCC), Reorganization
Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70 percent of the company’s workforce, only weeks after Bristol Myers Squibb abandoned its clinical collaboration program with Nektar on bladder cancer and renal cell carcinoma.
Nektar Therapeutics said on April 14 the company had stopped all clinical trials involving the drug developer’s key cancer drug bempegaldesleukin following its failure in multiple studies, dragging Nektar shares down 23% in after-market trading.
Bristol Myers Squibb announced results from an extended study to evaluate the long-term effects of taking the cardiovascular drug mavacamten.
Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors.